PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
19856009-8	2009	Treatment of cells with inhibitors of the isoprenoid biosynthetic pathway results in marked changes in GPP levels: the HMG-CoA reductase inhibitor lovastatin decreases GPP levels by over 50%, while the FPP synthase inhibitor zoledronic acid increases GPP levels 16- to 107-fold.	geranyl diphosphate	103-106	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	119-136	
19856009-8	2009	Treatment of cells with inhibitors of the isoprenoid biosynthetic pathway results in marked changes in GPP levels: the HMG-CoA reductase inhibitor lovastatin decreases GPP levels by over 50%, while the FPP synthase inhibitor zoledronic acid increases GPP levels 16- to 107-fold.	geranyl diphosphate	168-171	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	119-136